Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia / Castration-Resistant Prostate Cancer
Conditions
Sponsors
Bristol-Myers Squibb International Corporation
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: - Participated in and completed a previous dasatinib protocol (including but not limited to CA180056, CA180363 or CA180227) and is deemed by the investigator to be deriving benefit from dasatinib as defined by the previous protocol. - Receiving dasatinib at the time of signature of informed consent - Males and Females, ages 18 and older Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 50 F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: - All patients previously discontinued from a dasatinib study for any reason - Any serious or uncontrolled medical disorder or active infection that would impair the ability of the subject to receive protocol therapy - History of allergy to dasatinib
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: The purpose of this study is to continue to provide dasatinib to patients that are currently participating in another dasatinib trial that is ending and for which there is no other option to provide dasatinib;Secondary Objective: Not applicable;Primary end point(s): Number of subjects who received dasatinib treatment and duration of treatment will be collected;Timepoint(s) of evaluation of this end point: End of Study | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): All SAEs and AEs will be collected;Timepoint(s) of evaluation of this end point: End of Study | — |
Countries
Poland
Contacts
Public ContactEU Start Up Department
Bristol-Myers Squibb International Corporation
Outcome results
None listed